Physician profile
Allison E Miller
NPI 1538677497
$10,680.05
in general payments reported to CMS, 2019-2025
42 companies · $2,181 in 2025
The $2,181 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $914 · 2023: $3,395 · 2024: $4,071 · 2025: $2,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,706 · Consulting Fee: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,706.38 |
| Consulting Fee | $940.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,535.29 | 2022-2025 | |
| Emd Serono, INC. | $1,809.09 | 2022-2025 | Mavenclad |
| Biogen, INC. | $843.23 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Lilly USA, LLC | $463.87 | 2022-2025 | Emgality, Reyvow, Kisunla |
| Ucb, INC. | $409.45 | 2023-2025 | Briviact, Rystiggo, Nayzilam |
| Pfizer INC. | $390.66 | 2023-2025 | |
| Tg Therapeutics, INC. | $316.47 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $241.12 | 2024-2025 | |
| Amgen INC. | $232.92 | 2022-2025 | Uplizna, Aimovig |
| Lundbeck LLC | $179.48 | 2024 | Vyepti |
| Jazz Pharmaceuticals INC. | $137.72 | 2023-2024 | |
| Catalyst Pharmaceuticals, INC. | $135.86 | 2023-2024 | Fycompa |
| Teva Pharmaceuticals USA, INC. | $134.75 | 2023-2025 | Austedo Xr, Austedo Xr |
| Sumitomo Pharma America, INC. | $132.92 | 2023-2024 | Aptiom |
| Neurelis, INC. | $122.42 | 2023-2025 | Valtoco |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $116.24 | 2022 | |
| Argenx US, INC. | $116.13 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Mdd US Operations, LLC | $111.96 | 2024 | Apokyn |
| Alexion Pharmaceuticals, INC. | $107.92 | 2024 | Ultomiris |
| Amneal Pharmaceuticals LLC | $107.15 | 2023-2025 | Crexont, Rytary |
| Neurocrine Biosciences, INC. | $103.70 | 2024-2025 | Ingrezza |
| Grifols USA, LLC | $87.08 | 2024-2025 | Gamunex-C |
| Axsome Therapeutics, INC. | $84.23 | 2024-2025 | Auvelity, Symbravo |
| Averitas Pharma INC. | $77.40 | 2023-2024 | Qutenza |
| Impel Pharmaceuticals INC. | $75.10 | 2022-2023 | Trudhesa |
| Allergan, INC. | $62.51 | 2021 | |
| Genentech USA, INC. | $62.42 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Xeris Pharmaceuticals, INC. | $61.79 | 2024-2025 | Keveyis |
| Vanda Pharmaceuticals INC. | $54.40 | 2024 | Ponvory |
| Supernus Pharmaceuticals, INC. | $50.48 | 2024 | Qelbree |
| Janssen Pharmaceuticals, INC | $37.13 | 2021 | |
| Acorda Therapeutics, INC | $35.73 | 2023-2024 | Ampyra, Inbrija |
| Novo Nordisk INC | $33.28 | 2025 | Wegovy |
| Csl Behring | $32.15 | 2023 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $30.31 | 2024 | Hyqvia |
| Genzyme Corporation | $28.41 | 2024 | |
| Medtronic, INC. | $26.97 | 2023 | Sensight |
| Sk Life Science, INC. | $26.40 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.84 | 2024 | Wainua |
| Acadia Pharmaceuticals INC | $17.95 | 2024 | Nuplazid |
| Celgene Corporation | $14.28 | 2025 | Zeposia |
| Kyowa Kirin, INC. | $13.84 | 2024 | Nourianz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.